venBio Partners’s ALX Oncology ALXO Stock Holding History

venBio Partners’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25.8M	Buy	12,884,638 +3,184,713	+33%	+$6.07M	9.21%	3
2025 Q4	$11M	Hold	9,699,925	–	–	5.07%	4
2025 Q3	$17.8M	Hold	9,699,925	–	–	10.06%	3
2025 Q2	$4.03M	Hold	9,699,925	–	–	3.51%	5
2025 Q1	$6.04M	Hold	9,699,925	–	–	4.89%	5
2024 Q4	$16.2M	Hold	9,699,925	–	–	9.49%	4
2024 Q3	$17.7M	Hold	9,699,925	–	–	9.08%	6
2024 Q2	$58.5M	Hold	9,699,925	–	–	25.26%	2
2024 Q1	$108M	Hold	9,699,925	–	–	38.37%	1
2023 Q4	$144M	Hold	9,699,925	–	–	21.65%	2
2023 Q3	$46.6M	Hold	9,699,925	–	–	13.2%	3
2023 Q2	$72.8M	Hold	9,699,925	–	–	26.36%	2
2023 Q1	$43.8M	Hold	9,699,925	–	–	24.3%	2
2022 Q4	$109M	Hold	9,699,925	–	–	33.89%	2
2022 Q3	$92.8M	Hold	9,699,925	–	–	21.48%	2
2022 Q2	$78.5M	Hold	9,699,925	–	–	22.34%	1
2022 Q1	$164M	Hold	9,699,925	–	–	36.34%	1
2021 Q4	$208M	Hold	9,699,925	–	–	37.55%	1
2021 Q3	$716M	Hold	9,699,925	–	–	71.37%	1
2021 Q2	$530M	Hold	9,699,925	–	–	62.6%	1
2021 Q1	$715M	Hold	9,699,925	–	–	67.97%	1
2020 Q4	$836M	Hold	9,699,925	–	–	73.8%	1
2020 Q3	$366M	Buy	+9,699,925	New	+$381M	55.63%	1

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

venBio Partners's ALXO Position: Q1 2026 in Review

venBio Partners increased its ALX Oncology (ALXO) stake by 33% in Q1 2026, buying an estimated $6.07M and bringing the position to 12,884,638 shares worth $25.8M. The position accounts for 9.21% of the portfolio, ranked #3.

venBio Partners first reported a position in ALXO in Q3 2020 and has held it in 23 quarters since. The position peaked at $836M in Q4 2020. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

venBio Partners held 12,884,638 shares of ALX Oncology worth $25.8M as of Q1 2026.
venBio Partners bought 3,184,713 ALX Oncology shares in Q1 2026, an estimated $6.07M.
ALX Oncology made up 9.21% of venBio Partners's portfolio in Q1 2026, its #3 holding.
venBio Partners first reported a position in ALX Oncology in Q3 2020 and has held it in 23 quarters since.
venBio Partners's ALX Oncology position peaked at $836M in Q4 2020.
69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on venBio Partners's 13F filing for Q1 2026, filed 15 May 2026.